INTRODUCTION
Patients on chronic hemodialysis are at increased risk of Hepatitis C virus (HCV) infection, which is widely recognized as one of the main causes of acute and chronic hepatitis, cirrhosis, and hepatocellular carcinoma. [1] [2] [3] As the disease is almost always asymptomatic until the very late stages, the diagnosis is often made after a positive screening result for anti-HCV antibody (Ab) for blood donation, high-risk settings, surgical or hospital screenings, following the casual finding of raised alanine aminotransferase (ALT) levels during check-up. 4 HCV has global public health relevance, as it is endemic worldwide and although there are varying prevalence rates in different regions of the world, it impacts both developed and developing countries. 5 In 2017, the Portuguese National Program for Viral Hepatitis Report estimated a 1.1% prevalence for HCV infection. 6 HCV is both a cause and a consequence of renal impairment: it may induce renal disease and has a higher prevalence among chronic kidney disease (CKD) subjects undergoing hemodialysis than in the general population due to medical procedures and is mainly related to parenteral exposure. 2, 3, 7 Since the HCV is transmitted primarily through percutaneous blood exposure 7 , the number of years spent on dialysis therapy has been identified as an independent risk factor for HCV infection in hemodialysis patients. 8 There is a window period between acute infection and antibody production that may be more prolonged in those patients due to the immunodeficiency state. 1, 9 In The diagnostic limitation of antibody assays is that a positive result will not distinguish the stage of HCV infection (inactive, or whether acute or chronic if active); it only indicates a previous exposure to HCV. 2, 14 For this purpose, direct viral assays such as HCV-RNA are needed. Furthermore, by analyzing the presence of anti-HCV antibodies in a general population at an unknown risk, it is fairly common to detect low-level anti-HCV Ab positivity, with no definite classification by the additional tests. This analysis, which currently uses highly sensitive methods, requires the use of specific technology such as Polymerase Chain Reaction (PCR) or other RNA amplification methods and instrumentation, and the availability of a further sample or withdrawal with a time of response that can amount to several days. 4, 12 Like HCV-RNA, HCV Ag is also detected in the serum or plasma long before antibodies to HCV: the antibody window can be extended up to 12 weeks, whereas HCV Ag is usually detectable within 2-3 weeks of infection, almost simultaneously with HCV-RNA detection with molecular biology techniques. 15 A positive result for HCV Ag will confirm the viral replication activity. 4 ARCHITECT® HCV Antigen assay is a chemiluminescent microparticle immunoassay for the quantitative determination of core antigen of the HCV in human serum and plasma which employs microparticles coated with anti-HCV monoclonal antibodies that capture the HCV core Ag. The assay can be performed on the same sample and with the same instrumentation used for antibody detection. A running time of only 30 min for a single test allows high throughput and a quick clinical response. In some studies, the test demonstrated a specificity of ≥ 99.5% and a sensitivity of ≤ 3.00 fmol/L. 16 The overall cost, high technical skill requirement and long incubation time limit the applicability of direct viral detection methods, such as PCR, for mass screening of HCV infection. Therefore, the next technological development must replace the existing technology with a faster, more reliable and equally accurate analysis, while employing ubiquitous technology and consequently highly reducing costs. 14, 17, 18 
MATERIAL AND METHODS
We performed a prospective study of patients with CKD stage 5 or on hemodialysis in the Centro Hospitalar do Médio Tejo hemodialysis unit between March and August of 2017. Patients were screened by anti-HCV Ab and total ARCHITECT® HCV Antigen assay and those with one or both positive results were submitted to real time PCR for determination of the virus and viral load quantification.
Four milliliters of blood were collected in a tube by venipuncture from each patient in EDTA-treated or dry-plasma tubes, immediately centrifuged for serum separation and transferred to the immunohemotherapy lab.
All samples were tested for HBs Ag, anti-HCV Ab and HCV core Ag assay, using Abbot ARCHITECT® 2000iSR, a chemiluminescence immunoassay, according to the instructions provided by the manufacturer. The positive samples for anti-HCV Ab were also tested for HCV-RNA using Abbott m24sp for extraction and Abbott m2000 RealTime System for amplification.
Patient charts and documents were reviewed by the investigator. Data collected comprised demographic information, renal disease etiology and viral status.
Statistical analysis was performed using SPSS version 23 for Mac OS X (version 23.0, SPSS, Chicago, Ill., USA). Categorical variables are presented as frequencies and percentages, and continuous variables as means and standard deviations. All reported P values are two-tailed, with a P value of 0.05 indicating statistical significance.
The sensitivity and specificity of the HCV core Ag test were calculated according to the standard formula. Cohen's κ test was run to determine if there was agreement between HCV RNA and HCV core Ag assays.
RESULTS
Seventy-seven patients with CKD stage 5 or on chronic hemodialysis were analyzed in this prospective study. The majority of the patients (67.5%) were males and the mean age was 72.7314.05 years, ranging from 23 to 101 years. Sixty-seven (87%) were on hemodialysis and the duration of hemodialysis was 24.87±32.48 months, ranging from 1 to 235 months. Patients demographic data and characteristics are presented in Table 2 .
From the total sample of 77 patients, 70 (90.9%) had anti-HCV Ab negative serum samples, and the same patients had also HCV core Ag negative. The rate of HCV infection among HCV Ab negative hemodialysis patients was null. The 7 patients that had a positive Anti-HCV Ab were subjected to HCV core Ag followed by HCV RNA, of which two males (2.6%) were positive in both tests. The first male had CKD stage 5, was 54 years old, had 45.53 fmol/L of HCV core Ag and 1 124 930 IU/mL HCV RNA copies, while the second male had one month of hemodialysis, was 89 years old, had 471.38 fmol/L of HCV core Ag and 98550 IU/mL HCV RNA copies.
No HCV core Ag positive with negative Anti-HCV Ab patients were found, so it was not possible to calculate the seroconversion time window.
Despite the small sample size, it was decided to run a Cohen's κ test to determine if there was agreement between HCV RNA and HCV core Antigen assays on 7 individuals with positive Anti-HCV Ab. The two tests had a perfect measurement agreement (Kappa 1, p<0.008). Comparing the HCV core Ag analysis with real time PCR for HCV RNA measurement, considered gold standard for HCV infection determination in this patient population, there were no false negatives or false positives and sensitivity and specificity were 100% for this sample.
Port J Nephrol Hypert 2019; 33(2): 87-90 89 DISCUSSION One limitation of the earlier HCV core Ag assays was the lower sensitivity compared to HCV RNA assays. Currently, the sensitivity of the available HCV core antigen assay, by Abbott, has been improved to about 3.00 fmol/L (0.06 pg/mL). 12 An HCV core Ag assay can be useful in an HCV infection diagnostic algorithm with this newer, more sensitive, assay, especially in a dialysis population that requires frequent screenings due to its high risk condition. 12 Some papers focusing on dialysis patients showed that a number of anti-HCV negative patients could be identified as infected by HCV with a positive HCV core Ag assay. 5, 15 The use of this test will depend on the potential for cost saving in the diagnostic of HCV infection in a population setting. Thus, anti-HCV positive results would be reflexed to HCV core Ag testing, and additional HCV RNA testing would only be required if HCV core Ag was negative, and potential confirmation of anti-HCV with Recombinant ImmunoBlot Assay (RIBA) would only be necessary when both HCV core antigen and HCV RNA were negative. 12 This sequential approach (antibody, antigen and RNA) is also beneficial from a cost-effective perspective 19, 20 , ensuring the best relationship between invested resources and identification of subjects with active infection over the conventional approach of testing for antibodies and then for HCV-RNA. 4 Concerning sensitivity, in dialysis patients the search for HCV core Ag instead of HCV-RNA has proven effective to verify HCV incidence 4, 15 : in one study, where all dialysis patients were individually tested for HCV RNA, only one HCV RNA positive patient was found to be HCV core Ag negative; however, this response could have been caused by the low HCV viral load of HCV RNA < 100 IU/mL that was verified. 5 Accurate diagnosis of asymptomatic HCV infection is critical not only to reduce the rates of HCV-associated morbidity and mortality, but also to reduce the chances of nosocomial transmission. 16 Antibody spread through hemodialysis devices is one of the main reasons to look for a simple and reliable diagnostic method for HCV infection, even before anti-HCV Ab production in this population of patients, as a critical step for the control of infection spread in hemodialysis units. 4 The positive results verified after testing with HCV core Ag substantiate the authors' opinion that using this test as a screening tool paired with anti-HCV Ab is a cost-effective and reliable test for hepatitis C detection and control. As previously stated, hemodialysis patients perform an HCV screening at least two-times a year. Every time a positive anti-HCV Ab result is found, an expensive and prolonged HCV-RNA test has to be performed; these patients also have to undergo hemodialysis in a dedicated machine while waiting for this result, something which is time and resource-consuming for the hemodialysis unit. As was demonstrated, the HCV core Ag assay had a perfect measurement agreement when compared with HCV-RNA, and its sensitivity and specificity were 100% in a 30-minute test, which is even superior to the manufacturer's indications. The results make us confident that, with future routine use in our hemodialysis unit, patients can be referred to infectiology earlier when required.
Unfortunately, we did not have any HCV core Ag positive with negative Anti-HCV Ab, so we could not calculate the seroconversion time window and acquire any experience in this topic.
Moini et al presented similar results to the ones presented in this paper and formed the same opinion: HCV core Ag testing can be used as a sensitive method for HCV infection screening in hemodialysis and end-stageend-stage renal disease patients. 1 In conclusion, in this study we establish, by comparing immunoassay methods for HCV core Ag detection with the gold standard (RT-PCR for detection of HCV RNA), that the HCV core Ag detection test could be used as an effective screening test in patients on hemodialysis based on its accuracy, simplicity and low expense. However, due to our small sample size, further studies should be performed to improve the robustness of the data. The bibliographic research found other papers that corroborate our findings and impressions with HCV core Ag detection tests. 14, 17, 18, [21] [22] [23] Hepatitis C Virus Core Antigen Test: an HCV RNA screening alternative in end-stage renal disease and hemodialysis? Table 2 Demographic 
